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ABSTRACT 
Intellectual disability (ID) is a common morbid condition with a wide range of etiologies.  The 
list of monogenic forms of ID has increased rapidly in recent years thanks to the implementation 
of genomic sequencing techniques.  In this study, we describe the phenotypic and genetic 
findings of 67 families (104 patients) all with novel ID-related variants.  In addition to 
established ID genes, including ones for which we describe unusual mutational mechanism, 
some of these variants represent the first confirmatory disease-gene links following previous 
reports (TRAK1, GTF3C3, SPTBN4 and NKX6-2), some of which were based on single families.  
Furthermore, we describe novel variants in 14 genes that we propose as novel candidates 
(ANKHD1, ASTN2, ATP13A1, FMO4, MADD, MFSD11, NCKAP1, NFASC, PCDHGA10, 
PPP1R21, SLC12A2, SLK, STK32C and ZFAT).  We highlight MADD as a particularly 
compelling candidate in which we identified biallelic likely deleterious variants in two ID 
families.  We also highlight NCKAP1 as another compelling candidate in a large family with 
autosomal dominant mild intellectual disability that fully segregates with a heterozygous 
truncating variant.  The candidacy of NCKAP1 is further supported by its biological function, 
and our demonstration of relevant expression in human brain.  Our study expands the locus and 
allelic heterogeneity of ID and demonstrates the power of positional mapping to reveal unusual 
mutational mechanisms.    
 
  
INTRODUCTION 
Intellectual disability (ID) is a common morbidity that affects 1-3% of the population 1; 2.  The 
resulting functional impairment varies depending on the severity of ID, which ranges from mild 
to severe as quantified by the intelligence quotient (IQ) score.  The etiology of ID is highly 
heterogeneous although genetic forms are increasingly recognized as a major etiological 
category.  De novo genetic and genomic variants account for at least 50% of severe ID in outbred 
populations 3.  In contrast, the majority of ID in highly inbred populations is caused by recessive 
mutations 4; 5. 
The recent expansion in the use of genomic sequencing techniques (primarily whole-exome 
sequencing) has resulted in a rapid expansion of the genetic determinants of ID.  In the case of 
dominant causes, very large sequencing projects have concluded that the nearly all major ID 
genes have likely been identified 6.  This appears to be in striking contrast to recessive ID where 
recent large sequencing projects have revealed very little overlap in their lists of novel candidate 
genes, which suggests that a significant proportion of recessive ID genes have yet to be identified 
4; 7-9.  
Consanguinity loops are not only helpful in facilitating the discovery of novel recessive disease 
genes, including ID genes, but they also facilitate the occurrence of homozygous truncating 
(knockout) alleles in genes previously reported as candidates, which strongly corroborates those 
tentative disease-gene links 10.  Additionally, consanguinity can unmask recessive mutations in 
genes that are only known to cause diseases in an autosomal dominant fashion 11.  This can lead 
to a remarkably different phenotype from the previously reported dominant one 5; 12-14.  Finally, 
certain classes of pathogenic mutations may evade detection/interpretation by the typical 
genomic sequencing and only come to focus with the help of positional mapping aided by 
consanguinity 15.  In this study, we attempted to exploit the above advantages of consanguinity to 
expand the morbid genome of ID.   
 
MATERIALS AND METHODS 
Human Subjects 
All patients with documented ID or significant component of cognitive impairment in the setting 
of developmental delay in a young child were eligible.  Only patients in whom we identified 
variants that potentially explain their phenotype were included.  Those with potentially causal 
variants that are not novel were excluded.  Available family members were recruited for 
segregation analysis as appropriate.  A written informed consent was obtained from all subjects 
prior to participation in accordance with a KFSHRC IRB-approved research protocol (RAC# 
2121053). 
Mutation Identification 
All subjects with negative family history had molecular karyotyping performed as described 
before4; 16.  Only those in whom normal results were obtained were included in subsequent 
analysis.  Specifically, a previously described multigene panel (599 genes) were used to screen 
for mutations in known ID genes 17.  If negative, we proceeded with autozygome analysis and 
whole exome sequencing (WES) as described before 17.  Some patients were directly tested by 
clinical WES.  Variant classification was according to the recent ACMG guidelines 18.  For PM2 
score, we used gnomAD as well as an in-house ethnically matched database of 2,363 exomes and 
1,607 neuro gene panels.  We only included cases in whom pathogenic or likely pathogenic 
variants were identified.  The only exceptions are those in whom variants in candidate genes 
were identified.  These were included for the purpose of proposing novel candidate genes.  
Candidacy of these novel genes was based on several factors as described before 4; 16.  Sanger 
confirmation was performed for all reported variants and segregation with the phenotype was 
confirmed whenever samples from relatives were available.   
RTPCR and Molecular Cloning 
RNA isolation and gene-specific RTPCR were as described 19.  PCR amplified product was 
subjected to molecular cloning into sequencing vector pGEM-T Easy (Promega) followed by 
sequencing with SP6/T7 polymerase primers. 
Tissue Collection 
Samples were collected from brains donated to the Queen Square Brain Bank for Neurological 
Disorders, Institute of Neurology, University College London, UK. The donations were made 
according to ethically approved protocols, and tissue at Queen Square Brain Bank is stored under 
a license issued by the Human Tissue Authority (No. 12198). 
Computational structural analysis of mutants 
Sequences were retrieved from the Uniprot database. SwissModel  and RaptorX 20; 21 were used 
to produce homology models.  RaptorX was used for prediction of secondary structure and 
protein disorder.  QUARK 22 was used for ab initio structural modeling. Models were manually 
inspected, and mutations evaluated, using the Pymol program (pymol.org). 
Immunohistochemistry 
Immunohistochemistry Formalin-fixed paraffin-embedded tissue blocks from the frontal cortex, 
hippocampus and cerebellum of normal adult brains were used. Immunohistochemistry for 
NCKAP1 (1:750; Novus Biologicals, Littleton, CO) was performed using a standard 
avidin/biotin technique with chromogen diaminobenzidine. Briefly, eight-micrometer-thick 
sections were placed in methanol/H2O2 solution to neutralize endogenous peroxidase activity. 
After pressure cooking in citrate buffer (0.1M) at pH 6.0, sections were placed in 10% non-fat 
milk to reduce non-specific binding, followed by incubation in the primary antibody overnight at 
40C.   After washes in PBS, the sections were incubated with biotinylated secondary antibody 
(Vector Laboratories, Burlingame, CA) antibody, then washed off and incubated in the avidin-
biotin complex solution. The immunoreaction was visualized by treating the sections with 
diaminobenzidine/H2O2 solution and then counterstaining with Mayer’s hematoxylin. 
 
RESULTS 
We report 104 patients representing 67 families with novel alleles in known, tentative or novel 
candidate disease genes.  A list of these variants and the corresponding clinical phenotypes is 
provided in Table S1; detailed clinical description is provided in Table S2.   
Expanding the Allelic Heterogeneity of Known ID Genes 
Among the 67 families we describe in this study, 47 had potentially causal variants in genes with 
established link to ID.  With one exception, none of these alleles was a common founder 
mutation, consistent with the notion that the overwhelming majority of these had been identified 
and reported by us in previous work 5.  The sole exception was a novel variant in SPG20 in four 
apparently unrelated families who all shared the core features of ID and growth hormone 
deficiency of Troyer syndrome (Figure 1A).  At least one of these families had had “negative” 
investigation by exome sequencing.  In hindsight, this variant was most likely missed at the stage 
of interpretation because it is consistently predicted to be non-deleterious at the protein level by 
different in silico tools.  However, by running “SpliceAid” tool, we found that this variant 
predicts loss of the important exonic splicing suppressor.  Indeed, RTPCR followed by cloning 
confirmed that the normal transcript is largely replaced by an aberrant transcript with 25 bps 
deletion (Figure 1C-D).  Reassuringly, autozygome analysis confirms that three of these families 
(the fourth was not available for genotyping) map to the SPG20 locus (Figure 1B).  Another 
unusual mutational mechanism was the finding of a homozygous apparently loss of function 
mutation in CDH15, a gene that had only been reported in the context of autosomal dominant ID 
23.  The phenotype we observed in that family is similarly non-syndromic ID (Table S2).   
Confirming the Candidacy of Previously Reported Candidate ID Genes 
A single missense variant in GTF3C3 was very recently reported as a novel candidate cause of 
ID 8.  In 15DG0315, we observed a homozygous splicing (+3) variant 
(NM_012086.4:c.1382+3A>G), which we confirmed by RTPCR to result in skipping of exon10 
and part of exon11 (Figure S1B,C).  However, we note that our patient has profound secondary 
microcephaly with a characteristic facial appearance (Figure S1A).  It is possible that the more 
severe nature of our variant compared to that by Reuter et al led to the more severe phenotype.  
Future cases will be required to further delineate this novel syndrome.  Similarly, a single 
nonsense variant in SPTBN4 was reported very recently to cause ID associated with congenital 
myopathy, deafness, and neuropathy 24.  In 16DG1625, the phenotype we observed in the context 
of a different homozygous truncating variant was a predominantly central nervous system 
phenotype in the form of global developmental delay and diffuse T2 hyper-intense signal 
abnormality predominantly in the subcortical white matter.   
In addition to the above genes that had been reported on the basis of single variants, we also 
identified variants in genes reported only once but with multiple variants.  These include the very 
recently reported TRAK1 and NKX6-2 25; 26.   
Identification of Novel Candidate ID Genes 
We propose 14 genes (in 15 families) not previously linked to any Mendelian disease in humans 
as potential ID genes.  Justification for their selection is given in Table 1 along with detailed 
phenotypic features. Two such genes deserve a special mention.  Biallelic variants were 
identified in MADD in two families.  One Saudi family was homozygous for 
NM_003682.3:c.2930T>G:p.(Val977Gly) and were able to identify a second family from USA 
that is compound heterozygous for NM_003682.3:c.593G>A:p.(Arg198His) and 
NM_003682.3:c.979C>T:p.(Arg327*)).  MADD is a regulator of  neurotransmitter release and 
mouse model exhibits severe neuronal defects with early lethality 27; 28.   3D modeling of these 
missense variants in MADD  supports the pathogenicity of identified variants by in silico analysis 
(Figure 2).  Arg198 and Arg327 are located in the DENN domain.  The structure of the MADD 
DENN domain can be inferred based on similarity to the crystal structure of the human 
DENND1B DENN domain, bound to the Rab GTPase (PDB 3tw8) 29 (Figure 2A). For structure 
modeling, we deleted the linker regions between the DENN domains, based on DENN domain 
sequence alignments and predictions of the secondary structure elements and protein disorder. 
This truncated MADD DENN domain has a 25 % sequence identity to the DENND1B DENN 
domain (which also has loop deletions to allow crystallization). Arg198 is located in the 3D 
homology model on the outside of Alpha-helix H2 of the so-called longin module of the N-
terminal half (Figure 2A) 29.  This longin domain forms part of the GTPase interaction site in 
DENND1B. The GTPase binding site is well conserved in MADD, however the H2 region is 
distant from the GTPase site (Figure 2A).  Given that Arg198 is surface exposed, a histidine in 
position 198 would not lead to steric clashes, but the shortening of the side chain and the loss of 
a positive charge might affect intra- or intermolecular interactions.  The precise effect of the 
Arg198His mutation cannot be predicted, because of a lack of structural and functional 
knowledge.  The Arg327* truncation clearly demolishes the second half of the DENN domain, 
including the GTPase binding site (Figure 2A). The resulting protein is expected to be highly 
instable and to have lost most, if not all of its functions (including GTPase binding).  Leu977Arg 
(corresponding to Leu1040Arg in the canonical isoform1) is located in the C-terminal region of 
MADD.  Structure and function are unknown, but this region is predicted to be stably folded into 
a ~110 residue helical domain. Ab initio structure predictions of this region suggest that Leu977 
is located centrally on a hydrophobic surface of an Alpha-helix (Figure 2B).  This positioning is 
compatible with either Leu977 forming part of the hydrophobic core of the protein domain, or, 
alternatively, forming part of a hydrophobic interaction surface.  In both cases, the mutation 
Leu977Arg is expected to be highly disruptive, either severely destabilizing the 3D fold or the 
interaction. 
NCKAP1 was identified based on a large multigenerational family segregating non-syndromic 
mild ID (Figure 4).  Genomewide filtering of the exomic variants in the index revealed a 
heterozygous truncating variant in NCKAP1 as the most likely candidate.  Previous studies have 
suggested expression of NCKAP1 in human brain based on Northern blot analysis 30.  To 
confirm, we conducted immunohistochemical analysis on normal adult human brain sections 
using a commercially available antibody (Novus Biologicals, Littleton, CO) following a standard 
avidin/biotin technique with chromogen diaminobenzidine.  Our analysis revealed that NCKAP1 
is evident in cells ofvarious brain regions including Purkinje cells and dentate nucleus of the 
cerebellum, CA4 region and dentate gyrus of the hippocampus, and in frontal grey and white 
(Figure 4A-F).  We also note that ExAC (Exome Aggregation Consortium) lists a probability of 
loss of function intolerance (pLI) score of 1.00 indicating that this gene is extremely constrained 
against haploinsufficiency in the human genome.  
 
DISCUSSION 
ID is one of the most common indications for genomic testing 5.  The extreme clinical and 
genetic heterogeneity of this condition was key to the professional recommendation of 
performing molecular karyotyping as a first-tier test in these patients 31.  Although no similar 
recommendation has been made with respect to other genomic tests (panels, WES and whole-
genome sequencing), our experience and that of others strongly support their implementation as 
first-tier tests in those with positive family history and in parallel with molecular karyotyping in 
those with negative family history 4. 
The aim of this study is not to show the yield of genomic tests in the setting of ID.  Rather, we 
set out to specifically share with the clinical and molecular genetics community a large number 
of carefully annotated variants that potentially cause ID.  In the era of expanding use of public 
databases for the interpretation of variants, it is critical that individual efforts to annotate 
medically relevant variants are made available on timely basis 32.  In addition, our confirmation 
of the candidacy of genes with previously reported tentative link to disease is an important 
contribution to the publicly-funded efforts of improving the rigor with which disease-gene links 
are established for the purpose of clinical testing 33. 
For the candidate genes that we report for the first time in this study, we acknowledge that the 
disease-gene link is tentative since these are based on single families, with the exception of 
MADD.  However, sharing of these candidates can be very helpful in facilitating post-publication 
matchmaking and future confirmation as we have demonstrated for several genes in this study 34.  
Reassuringly, the strict selection criteria we apply by our Mendelian Genomics Program in this 
study has proven helpful in the past in enriching for genes that are likely to be confirmed by 
subsequent reports.  For example, of the 33 novel candidate genes we proposed in 2015, we note 
that 12 have now been reported to harbor deleterious variants that caused similar phenotypes in 
additional patients 16. 
Although we emphasized the candidacy of NCKAP1 and MADD, we note that the other 12 novel 
candidate genes have also been selected on the basis of relevant biological data as shown in 
Table 1.  For example, SLC12A2 encodes a Na-K-Cl cotransporter that is highly expressed in 
developing cortical neurons, is necessary for NGF-induced neurite outgrowth, regulates 
hippocampal neuronal development and has been implicated recently in schizophrenia risk 35-38.  
ANKHD1 regulated the development of neuroprogenitors 39.  MFSD11 encodes a putative solute 
carrier that is abundant in developing brain and has been implicated in regulating energy 
homeostasis 40.  NFASC encodes neurofascin, which has been found to be necessary for the 
formation of paranodal axo-glial junctions, which are in turn necessary for the propagation of 
nerve impulses 41.  SLK (STE20-LIKE PROTEIN KINASE) gene encodes a novel kinase that 
governs early cell signaling pathways like cell division, and the mouse model appears to 
recapitulate the human phenotype 42. 
In summary, we present a number of novel variants that we hope will contribute to the global 
endeavor of improving the medical annotation of the human genome for the benefit of families 
with various forms of intellectual disability. 
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FIGURE LEGENDS 
Figure 1. (A) Pedigrees and facial images of 4 families with SPG20 mutation. Note the lack of 
major facial dysmorphism. (B) Agileidiogramapper shows shared haplotype on Chr13. (C) 
RTPCR showing the aberrant transcript in SPG20. (D)  Diagram representing location of 
deletion In between exon3 and 4.  Chromatogram showing deletion of 25 bps in SPG20 
(NM_001142294.1:c. 988A>G: r.986-1010 del). Pt: patient; N: normal control. 
Figure 2 (A) Secondary structure representation of the homology model of the tripartite MADD 
DENN domain (residues 1 to 605, with truncated loop regions), based on the structure of the 
DENN domain from DENND1B (PDB 3tw8). The MADD DENN domain is colored gray up to 
residue 326, and orange thereafter, to highlight the region absent in the Arg327* mutant. R198 is 
shown in green. The GTPase (yellow) was taken from the superimposed structure of DENND1B 
bound to Rab (3tw8). (B) Illustration of an ab initio 3D structure prediction of the MADD 
domain containing Leu977 (L1040 in isoform1).  The Leu977 side chain is highlighted in green. 
Hydrophobic residues present on the same helix are colored in orange. 
Figure 3. (A) Pedigree showing multiple affected members. -/- denotes wild type and +/- denotes 
heterozygous mutation in NCKAP1.  (B) Facial features of affected girl showing mild 
hypertelorism. (C) Chromatogram of NCKAP1 heterozygous missense mutation. (D) Genomic 
organization of NCKAP1 and mutation in in exon 32. 
Figure 4. NCKAP1 expression in normal adult human brain. NCKAP1 protein expression is 
evident in various regions of the normal human adult brain as shown by NCKAP1 
immunohistochemistry. The protein is present in both neuronal and glial cells as shown in the 
Perkinjie cells (A, arrows) and dentate nucleus (B) of the cerebellum, CA4 region (C) and 
dentate gyrus (D) of the hippocampus, and frontal grey (E) and white matter (F). Scale bar: A,B: 
50μm; C-F: 50μm.  
Figure S1. A) Clinical features of patient with GTF3C3-related ID showing facial asymmetry, 
bilateral temporal narrowing, epicanthal folds, upslanting palpebral fissures, bulbous nose, and 
full cheeks. (C) Chromatogram showing skipping of exone10 and partial part of exon11.  
 
 
 
Table:1. Novel candidate genes identified in this study. Homo: homozygous change; Het: heterozygous change.  
Family Clinical synopsis 
(HPO Terms) 
Novel candidate gene and variant Zygosity Supporting evidences  
HC0342601
6 
Failure to thrive; Speech 
delay and language 
development; Microcephaly;  
Short stature; Anteriorly 
placed anus; Abnormal facial 
shape; Intrauterine growth 
retardation 
ANKHD1 
(NM_017747.2:c.7365dup:p.(His2456Serfs*1
3)) 
De novo Involved in cell survival, cell-cycle regulation, ion 
channel, cell survival, cell signaling, and protein–
protein interactions and apoptosis 
(PMID:16098192), segregated within family, pLI 
score of 1.00. 
15DG0307 Abnormal facial shape; 
hypospadias; chordee; Global 
developmental delay; 
Depressed nasal bridge; 
Frontal bossing; Abnormality 
of the frontal hairline; 
Microtia; anteverted nares; 
café au lait spot 
ASTN2 
(NM_014010.4:c.892G>C:p.(Asp298His)) 
Homo Associated with neurodegenerative disease and 
hippocampal volume (PMID:25410587 and 
28098162), segregated within family. 
13DG1545 Intellectual disability; 
Attention deficit 
hyperactivity disorder; 
Recurrent respiratory 
infections; Downslanted 
palpebral fissures; Prominent 
nose; Hyperplasia of the 
maxilla; Abnormality of the 
fingernails 
ATP13A1 
(NM_020410.2:c.1045G>A:p.(Glu349Lys)) 
Homo Protects from iron-induced neuro cytotoxicity 
(PMID: 25912790), segregated within family. 
13DG1202 Abnormal CNS myelination; 
Peripheral axonal 
neuropathy; Abnormality of 
the foot; Scoliosis; Drooling; 
Ulnar claw; Microcephaly; 
FMO4 (NM_002022.1:c.83C>A:p.(Pro28His)) Homo Identified by positional mapping and segregated 
within family. 
Areflexia; Intellectual 
disability 
72960215, 
150660542
0 
Speech delay and language 
development; Autism; Poor 
eye contact  
MADD 
(NM_003682.3:c.593G>A:p.(Arg198His) and 
NM_003682.3:c.979C>T:p.(Arg327*)) 
Compoun
d Het 
Critical regulator of neurotransmitter release in 
synapse and of neuronal viability (PMID: 11359932 
and 15007167) 
2616102 Global developmental delay; 
Failure to thrive;  Poor eye 
contact 
MADD 
(NM_003682.3:c.2930T>G:p.(Val977Gly)) 
Homo Critical regulator of neurotransmitter release in 
synapse and neuronal viability (PMID: 11359932 
and 15007167) 
15DG2492 Intellectual disability; Short 
stature; Abnormal facial 
shape; Abnormal heart 
morphology; Abnormality of 
the genitourinary system 
MFSD11  
(NM_001242532.1:c.143G>C:p.(Gly48Ala)) 
Homo Expressed in mouse brain particularly in excitatory 
and inhibitory neurons (PMID: 27272503) and 
segregated within family. 
12DG1370 Tip-toe gait; Intellectual 
disability; ; Speech delay and 
language development; 
Attention deficit 
hyperactivity disorder;  
Hypertelorism; 
Macrocephaly; Tall stature 
NCKAP1 
(NM_205842.2:c.3298G>T:p.(Glu1100*)) 
Hetero Expressed in the hippocampus and cerebral cortex 
in mouse brain and associated with Alzheimer's 
disease (AD) pathology (PMID: 11418237). Our 
expression studies of NCKAP1 on human brain 
clearly show abundant expression in human brain 
and segregated with in family members. pLI score 
1.00.  
14DG0056 Global developmental 
delay;Congenital laryngeal 
stridor; Hypertonia;  
Neonatal respiratory distress;  
Abnormal facial shape; Small 
anterior fontanelle; 
Recurrent respiratory 
infections; Hypertelorism; 
Hypotonia; Wide nasal 
bridge; Micrognathia; 
Glossoptosis; 
Hyperextensibility of the 
finger joints; 11 pairs of ribs 
NFASC 
(NM_001160331.1:c.1109G>C:p.(Arg370Pro)
) 
Homo Critical for Ranvier node maintenance and 
Myelination of axon Function (PMID: 28217083) 
and segregated within family. 
14DG1188 Intellectual disability; 
Abnormal facial shape; 
Bicuspid aortic valve; Cleft 
upper lip; Inguinal hernia; 
Recurrent otitis media; 
Microcephaly; 
Brachycephaly; Anteverted 
ears; Bulbous nose; Long 
philtrum; Thin upper lip 
vermilion; Downturned 
corners of mouth; Synophrys; 
Pes planus; Arachnoid cyst 
PCDHGA10 
(NM_018913.2:c.823G>A:p.(Glu275Lys)) 
Homo Cadherin family genes regulates neuronal network 
in the brain (PubMed: 10380929) and segregated 
within family. 
N010 Severe global developmental 
delay; Neonatal respiratory 
distress; Dilatation of lateral 
ventricles; Hypotonia; 
Generalized muscle 
weakness; Recurrent 
respiratory infections; 
Abnormal facial shape; Wide 
nasal bridge; Upslanted 
palpebral fissures; Coarse 
facial features; Generalized 
hirsutism; Low-set, 
posteriorly rotated ears; 
Thick lower lip vermilion; 
High, narrow palate; 
Hepatomegaly; Myopia; 
Rotatory Nystagmus; 
Areflexia; Abnormal CNS 
myelination; Cavum septum 
pellucidum; Enlarged cisterna 
magna 
PPP1R21 
(NM_001193475.1:c.2056C>T:p.(Gln686*)) 
Homo Segregated within family.  
SFH-871000 Global developmental delay; SLK (NM_014720.1:c.1414G>T:p.(Glu472*)) Homo Insertional mutagenesis of SLK gene in mouse 
Failure to thrive; Recurrent 
respiratory infections; 
Hydrocephalus; Cutis laxa; 
Joint hyperextensibility; 
Hepatomegaly; Hypotonia; 
Generalized muscle 
weakness; Strabismus; 
Oculomotor apraxia; 
Ventriculomegaly 
 shows developmental defects along with neuronal 
and skeletal defects (Mouse Genome Informatics 
(MGI)) 
KFMC-
435029086 
Global developmental delay; 
Failure to thrive; Central 
hypotonia; 
Microcephaly;Neonatal 
respiratory distress; 
Recurrent aspiration 
pneumonia; Osteopenia 
SLC12A2 (NM_001046.2:c.2617-2A>G) Homo Involved in hippocampal neuronal development 
(PMID: 23921125) and segregated within family. 
10DG0720 Global developmental delay; 
Seizures; Microcephaly;  
hypertonia; Hypocalcemic 
seizures; Hypomagnesemia; 
strabismus; Pes planus; 
Hypocalcemia; 
Brachycephaly 
STK32C 
(NM_173575.2:c.451G>C:p.(Val151Leu)) 
Homo Associated with depression PMID: 24929637 and 
segregated within family. 
15DG2661 Global developmental delay; 
Hypotonia; Abnormal facial 
shape; Hypotonia; Hip 
dysplasia; Failure to thrive; 
Intrauterine growth 
retardation; Enlarged 
cisterna magna; 
Polycythemia; Coarse facial 
features; Hypertrichosis; 
Thick eyebrow; Upslanted 
palpebral fissure; High 
ZFAT 
 (NM_020863.3 :c.1199G>A:p.(Arg400Gln) ) 
Homo Peripheral T cell homeostasis and immune 
development (PMID: 22828507) and segregated 
within family. 
forehead; Strabismus; 
Prominent nose; Thin 
vermilion border; Prominent 
nasal tip; High, narrow 
palate; Arachnodactyly; 
Pectus excavatum; 
Generalized amyotrophy; 
Overlapping toe; osteopenia; 
11 pairs of ribs 
 
 
